How to promote the accessibility of technology in the era of hESC patents—A comparative analysis of the systems of the US and China
Open Access
- 21 September 2023
- journal article
- review article
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (10) , 1899-1904
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Limiting hESC patents in China under a dual‐value perspectiveEMBO Reports, 2022
- Rethink the patentability of human embryonic stem cell research findings: Relaxation based on benefit weighingStem Cell Reports, 2021
- From strict moral standards to ethical neutrality: a policy-guided shift in the patentability of human embryonic stem cells in ChinaStem Cell Research & Therapy, 2020
- Legitimacy of Experimental Use of Patented Research Tools by Chinese UniversitiesBiotechnology Law Report, 2020
- The limits of “ordre public” and “morality” for the patentability of human embryonic stem cell inventionsThe Journal of World Intellectual Property, 2018
- How human embryonic stem cells sparked a revolutionNature, 2018
- ‘Government Patent Use’: A Legal Approach To Reducing Drug SpendingHealth Affairs, 2016
- Interfacing of Science, Medicine and Law: The Stem Cell Patent Controversy in the United States and the European UnionFrontiers in Cell and Developmental Biology, 2015
- Generation of germline-competent induced pluripotent stem cellsNature, 2007
- The global stem cell patent landscape: implications for efficient technology transfer and commercial developmentNature Biotechnology, 2007